REDEFINING Liver Cancer Diagnostics with Metabolite Profiling

Liver cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer deaths worldwide with more than 700,000 new cases and 600,000 deaths each year. Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is most often a complication of cirrhosis. Half of HCC deaths occur in China, and high HCC rates in East and Southeast Asia are due to the high prevalence of chronic hepatitis B. In the United States and Europe, hepatitis C and alcohol-related cirrhosis cause the majority of HCC cases.

There are an estimated 3.2 million hepatitis C patients and 1.2 million hepatitis B patients in the United States, and up to 170 million worldwide. Approximately one in four chronic hepatitis C patients develop cirrhosis, on average about 20 years after being infected with hepatitis C. Up to 5% of hepatitis C patients with cirrhosis develop liver cancer each year.

Current diagnostic tests are not sufficiently reliable for early diagnosis of liver cancer and often lead to false positives. A late diagnosis of liver cancer limits treatment  to costly options that can mean a poor prognosis for the patient.

Matrix-Bio has developed a blood serum-based, metabolite profiling test for the early detection of HCC and monitoring patients with chronic hepatitis B and C. Matrix-Bio’s HCC test has demonstrated 95% accuracy in early studies.

 


CONNECT WITH MATRIX-BIO

If you have questions about Matrix-Bio’s early liver cancer detection test or about our investing and partnership opportunities, please contact:

Eric Beier, MD, MBA
ebeier@matrix-bio.com